A Phase 1 interventional study of Placebo and Midomafetamine in Startle Response, sponsored by Lykos Therapeutics. Completed at 1 site in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-04.
Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if MDMA impacts startle response in healthy participants.
The main question it aims to answer is: Does MDMA impact participant's performance on a startle test?
Researchers will compare healthy volunteers who have taken MDMA to those who have taken placebo.
Participants will first undergo a 1-hour startle test. The next day, they will be randomized to receive either MDMA or placebo followed by another startle test and vitals signs and blood measurements. Participants will return the next day for a final startle test. Their sleep will be tracked by a Fitbit device.
This is a randomized, blinded, placebo-controlled Phase 1 study that aims to evaluate the impact of 3,4-methylenedioxymethamphetamine (MDMA) on startle response.
This study will enroll healthy participants. At Visit 1, all participants will undergo a 1-hour startle test. Acoustic startle will be measured through assessing eye-blink response from the orbicularis oculi muscles in response to a 106 dB noise, using sensors under the eye. While watching the computer monitor, the participant will also experience several brief blasts of air directed at the throat.
At Visit 2 (24 hours later), participants will be randomized to receive 100 mg of MDMA or inactive placebo, after which they will undergo another startle test. Participants enrolled in the study who agree to do this will have their blood drawn to measure levels of oxytocin, and possibly other hormones or proteins, such as cortisol or brain-derived neurotrophic factor (BDNF). Measuring oxytocin will be blind to condition, and the decision will happen before randomization to either condition. Blood will be drawn before MDMA or placebo administration, and eight times afterwards.The researchers will measure pulse, blood pressure and temperature once before and six times after receiving MDMA or placebo, and study participants will complete a questionnaire about their experience.
At Visit 3, participants will return for a final startle test and recall task. Sleep will be measured via self-report and Fitbit during study participation.
Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 100 mg MDMA HCl on their second visit
Drug: Midomafetamine · Behavioral: Acoustic startle
Participants receive inactive placebo on their second visit
Drug: Placebo · Behavioral: Acoustic startle
Participants will receive inactive placebo on their second visit.
Also known as: inactive placebo, lactose
Participants will receive 100 mg midomafetamine HCl on their second visit
Also known as: 3,4-methylenedioxymethamphetamine, MDMA, midomafetamine HCl
Startle assessment
Also known as: startle test
EMG of right orbicularis oculi muscle
Description: Measure of startle response to noise after fear extinction training
Time frame: Four days post-enrollment
Systolic blood pressure pre-drug
Systolic blood pressure measured prior to administration of MDMA or placebo
Time frame: 5 minutes pre-drug
Systolic blood pressure 45 min post-drug
Systolic blood pressure measured 45 minutes after MDMA or placebo administration
Time frame: 45 minutes post-drug
Systolic blood pressure 1 h 15 min post-drug
Systolic blood pressure measured 1 hour 15 minutes after MDMA or placebo administration
Time frame: 1 hour 15 minutes post drug
Systolic blood pressure 1 h 45 min post-drug
Systolic blood pressure measured 1 hour 45 minutes after MDMA or placebo administration
Time frame: 1 hour 45 minutes post drug
Systolic blood pressure 3 h post-drug
Systolic blood pressure measured 3 hours after MDMA or placebo administration
Time frame: 3 hours post-drug
Systolic blood pressure 4 h post-drug
Systolic blood pressure measured 4 hours after MDMA or placebo administration
Time frame: 4 hours post-drug
Systolic blood pressure 5 h post-drug
Systolic blood pressure measured 5 hours after MDMA or placebo administration
Time frame: 5 hours post-drug
Systolic blood pressure 6 h post-drug
Systolic blood pressure measured 6 hours after MDMA or placebo administration
Time frame: 6 hours post-drug
Diastolic blood pressure pre-drug
Diastolic blood pressure measured prior to MDMA or placebo administration
Time frame: 5 minutes pre-drug
Diastolic blood pressure 45 min post-drug
Diastolic blood pressure measured 45 minutes after MDMA or placebo administration
Time frame: 45 minutes post-drug
Diastolic blood pressure 1 h 15 min post-drug
Diastolic blood pressure measured 1 h 15 minutes after MDMA or placebo administration
Time frame: 1 hour 15 minutes post-drug
Diastolic blood pressure 1 h 45 min post-drug
Diastolic blood pressure measured 1 h 45 minutes after MDMA or placebo administration
Time frame: 1 hour 45 minutes post drug
Diastolic blood pressure 3 h post-drug
Diastolic blood pressure measured 3 hours after MDMA or placebo administration
Time frame: 3 hours post-drug
Diastolic blood pressure 4 hours post-drug
Diastolic blood pressure measured 4 hours after MDMA or placebo administration
Time frame: 4 hours post-drug
Diastolic blood pressure 5 hours post-drug
Diastolic blood pressure measured 5 hours after MDMA or placebo administration
Time frame: 5 hours post-drug
Diastolic blood pressure 6 hours post-drug
Diastolic blood pressure measured 6 hours after MDMA or placebo administration
Time frame: 6 hours post-drug
Pulse pre-drug
Pulse (assessing heart rate) measured prior to MDMA or placebo administration
Time frame: 5 minutes pre-drug
Pulse 45 min post-drug
Pulse (assessing heart rate) measured 45 min after MDMA or placebo administration
Time frame: 45 minutes post-drug
Pulse 1 h 15 min post-drug
Pulse (assessing heart rate) measured 1 hour 15 min after MDMA or placebo administration
Time frame: 1 hour 15 minutes post-drug
Pulse 1 h 45 min post-drug
Pulse (assessing heart rate) measured 1 hour 45 min after MDMA or placebo administration
Time frame: 1 hour 45 minutes post-drug
Pulse 3 h post-drug
Pulse (assessing heart rate) measured 3 hours after MDMA or placebo administration
Time frame: 3 hours post-drug
Pulse 4 h post-drug
Pulse (assessing heart rate) measured 4 hours after MDMA or placebo administration
Time frame: 4 hours post-drug
Pulse 5 h post-drug
Pulse (assessing heart rate) measured 5 hours after MDMA or placebo administration
Time frame: 5 hours post-drug
Pulse 6 h post-drug
Pulse (assessing heart rate) measured 6 hours after MDMA or placebo administration
Time frame: 6 hours post-drug
Body temperature pre-drug
Body temperature measured before MDMA or placebo administration
Time frame: 5 minutes pre-drug
Body temperature 45 minutes post-drug
Body temperature measured 45 minutes after MDMA or placebo administration
Time frame: 45 minutes post-drug
Body temperature 1 h 15 minutes post-drug
Body temperature measured 1 hour 15 minutes after MDMA or placebo administration
Time frame: 1 hour 15 minutes post-drug
Body temperature 1 h 45 minutes post-drug
Body temperature measured 1 hour 45 minutes after MDMA or placebo administration
Time frame: 1 hour 45 minutes post-drug
Body temperature 3 hours post-drug
Body temperature measured 3 hours after MDMA or placebo administration
Time frame: 3 hours post-drug
Body temperature 4 hours post-drug
Body temperature measured 4 hours after MDMA or placebo administration
Time frame: 4 hours post-drug
Body temperature 5 hours post-drug
Body temperature measured 5 hours after MDMA or placebo administration
Time frame: 5 hours post-drug
Body temperature 6 hours post-drug
Body temperature measured 6 hours after MDMA or placebo administration
Time frame: 6 hours post-drug
Plasma oxytocin (OT) levels predrug
In people who agree to it, blood collected to assess levels of oxytocin prior to MDMA or placebo administration on day of drug administration
Time frame: 5 min prior to drug administration
Plasma oxytocin (OT) levels 5 min post-drug
In people who agree to it, blood collected to assess levels of oxytocin approximately 5 minutes after MDMA or placebo administration
Time frame: 5 min post-drug administration
Plasma oxytocin (OT) levels 20 min post-drug
In people who agree to it, blood collected to assess levels of oxytocin approximately 20 minutes after MDMA or placebo administration
Time frame: 20 min post-drug administration
Plasma oxytocin (OT) levels 95 min post-drug
In people who agree to it, blood collected to assess levels of oxytocin approximately 95 minutes (approximately 1.5 h) after MDMA or placebo administration
Time frame: 95 min post-drug administration
Plasma oxytocin (OT) levels 110 min post-drug
In people who agree to it, blood collected to assess levels of oxytocin approximately 110 minutes after MDMA or placebo administration
Time frame: 110 min post-drug administration
Plasma oxytocin (OT) levels 185 min post-drug
In people who agree to it, blood collected to assess levels of oxytocin approximately 185 minutes after MDMA or placebo administration
Time frame: 185 min post-drug administration
Plasma oxytocin (OT) levels 200 min post-drug
In people who agree to it, blood collected to assess levels of oxytocin approximately 200 minutes after MDMA or placebo administration
Time frame: 200 min post-drug administration
Plasma oxytocin (OT) levels 240 min post-drug
In people who agree to it, blood collected to assess levels of oxytocin approximately 240 minutes after MDMA or placebo administration
Time frame: 240 min post-drug administration
Plasma oxytocin (OT) levels 300 min post-drug
In people who agree to it, blood collected to assess levels of oxytocin approximately 300 minutes after MDMA or placebo administration
Time frame: 300 min post-drug administration
Plan to share: No
Ran from Mar 2017 to primary completion in Aug 2020, 40 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine